NCT07236879 Artificial Intelligence for Diagnosing Diabetic Retinopathy in Primary Care
| NCT ID | NCT07236879 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospital de Clinicas de Porto Alegre |
| Condition | Diabetic Retinopathy |
| Study Type | INTERVENTIONAL |
| Enrollment | 922 participants |
| Start Date | 2024-08-08 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 922 participants in total. It began in 2024-08-08 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a clinical trial to evaluate the effects of universal screening for diabetic retinopathy (DR) and diabetic macular edema (DME) using artificial intelligence (AI) in the interpretation of fundus photographs obtained by trained nursing assistant using a portable fundus camera in a primary care setting, compared with images obtained by the same method, but interpreted by ophthalmologists.
Eligibility Criteria
Inclusion Criteria: * Adults (\> 18 years old) diagnosed with diabetes mellitus who agree to participate in the study. Exclusion Criteria: * Any contraindication for pharmacological mydriasis (such as knowledge of having closed-angle glaucoma, pregnancy). * Life expectancy less than 6 months
Contact & Investigator
Beatriz D Schaan, MD, PhD
PRINCIPAL INVESTIGATOR
Hospital de Clínicas de Porto Alegre
Frequently Asked Questions
Who can join the NCT07236879 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Diabetic Retinopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07236879 currently recruiting?
Yes, NCT07236879 is actively recruiting participants. Contact the research team at bschaan@hcpa.edu.br for enrollment information.
Where is the NCT07236879 trial being conducted?
This trial is being conducted at Porto Alegre, Brazil.
Who is sponsoring the NCT07236879 clinical trial?
NCT07236879 is sponsored by Hospital de Clinicas de Porto Alegre. The principal investigator is Beatriz D Schaan, MD, PhD at Hospital de Clínicas de Porto Alegre. The trial plans to enroll 922 participants.